{"entity":{"id":"criterium","kind":"company","name":"Criterium","aka":["Criterium, Inc.","Criterium Inc"],"tldr":"Criterium is a US company in Saratoga Springs, New York, that is the lead sponsor of four cancer trials in OnCo, all testing other makers' drugs: fruquintinib with TAS-102 in colorectal cancer and tucatinib, alpelisib or palbociclib combinations in breast cancer.","summary":"Criterium, Inc. is a company based in Saratoga Springs, United States (Wikidata Q140045287, which also gives its website). ClinicalTrials.gov classes it as an industry sponsor. It leads four trials recorded in OnCo, none of a compound of its own: NCT06992258 (phase 2, fruquintinib with TAS-102 against fruquintinib alone in refractory metastatic colorectal cancer), NCT05230810 (phase 1/2, alpelisib with tucatinib in PIK3CA-mutant HER2-positive metastatic breast cancer), NCT04567420 (DARE, phase 2, circulating tumour DNA-guided second-line adjuvant palbociclib and fulvestrant in high-risk ER-positive HER2-negative breast cancer) and NCT05458674 (phase 2, tucatinib with trastuzumab and eribulin in pretreated HER2-positive metastatic breast cancer). The cro-services type reflects that pattern; Criterium's own description of its business was not consulted.","asOf":"2026-09-22","links":[{"label":"Official website","url":"https://www.criteriuminc.com"},{"label":"Wikidata Q140045287","url":"https://www.wikidata.org/wiki/Q140045287"},{"label":"ClinicalTrials.gov: trials led by Criterium, Inc.","url":"https://clinicaltrials.gov/search?lead=Criterium%2C%20Inc."}],"tags":["ctgov-sponsor","wave5-sponsor"],"related":[],"cancers":["colorectal","breast-her2-positive","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06992258","nct05230810","nct04567420","nct05458674"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo content wave 5 (Wikidata, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-22"},"hq":"Saratoga Springs, New York","country":"US","companyType":"cro-services","website":"https://www.criteriuminc.com","investors":[],"funding":[]},"route":"/companies/criterium/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"trial":[{"id":"nct06992258","kind":"trial","name":"A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer","route":"/trials/nct06992258/"},{"id":"nct05230810","kind":"trial","name":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.","route":"/trials/nct05230810/"},{"id":"nct04567420","kind":"trial","name":"DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)","route":"/trials/nct04567420/"},{"id":"nct05458674","kind":"trial","name":"Tucatinib+Trastuzumab+Eribulin in HER2+ MBC","route":"/trials/nct05458674/"}]}}